Chronic Spontaneous Urticaria Market Insight, Epidemiology 

DelveInsight's Chronic Spontaneous Urticaria Market Insights Report 2034 delivers comprehensive analysis of current and projected market dynamics, individual company market shares, challenges, drivers, barriers, trends, and key pharmaceutical players operating in the Chronic Spontaneous Urticaria treatment landscape.

To read more about the latest highlights related to the Chronic Spontaneous Urticaria Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Chronic Spontaneous Urticaria Market Report

• The Chronic Spontaneous Urticaria market size in the 7MM (US, EU4, UK, and Japan) was valued at approximately USD 2,000 million in 2025, growing at a robust CAGR of 15.9% during the forecast period from 2025 to 2034 to reach USD 7,555 million by 2034.

• Leading Chronic Spontaneous Urticaria companies include Sanofi/Regeneron Pharmaceuticals, Celldex Therapeutics, Novartis, Incyte, Jasper Therapeutics, Evommune, and others driving innovation through various clinical trial phases.

• The United States is anticipated to hold a substantial share of the Chronic Spontaneous Urticaria market in 2024, with approximately USD 1 billion in market size, expected to grow at a CAGR of 14% during the forecast period. This growth can be attributed to increasing disease awareness, the presence of leading pharmaceutical companies, improved diagnostic capabilities, and the launch of emerging therapies.

To know more about why the United States is leading the market growth in the Chronic Spontaneous Urticaria Market, get a snapshot @ Chronic Spontaneous Urticaria Market Outlook 

Chronic Spontaneous Urticaria Market Dynamics

According to DelveInsight's estimates, approximately 3.2 million diagnosed prevalent cases of Chronic Spontaneous Urticaria were reported in the 7MM in 2024. The US accounted for nearly 18.5% of these cases, while the EU4 and UK represented around 44.3%, and Japan accounted for approximately 37.2% of total cases.

The International Diabetes Federation (IDF) 2021 data estimates that around 537 million people globally are living with diabetes, projected to reach 643 million by 2030. Additionally, GLOBOCAN 2022 reports approximately 19.98 million people worldwide were affected by various oncological disorders in 2022. These chronic conditions frequently coexist with Chronic Spontaneous Urticaria, driving market expansion.

Chronic Spontaneous Urticaria Market Segment Analysis

The Chronic Spontaneous Urticaria market is segmented by therapy class (Antihistamines, Biologics, Immunosuppressive Agents, Leukotriene Receptor Antagonists, and Others), end-user (Hospitals, Specialty Clinics, and Retail Pharmacies), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the therapy segment, biologics are projected to capture the largest revenue share, driven by their targeted mechanism of action and superior efficacy compared to conventional treatments. In 2024, biologics dominated the treatment landscape across the 7MM, capturing approximately USD 1 billion in revenue, followed by prescription antihistamines at around USD 490 million. This dominance is fueled by the approval of DUPIXENT (dupilumab) and the anticipated launch of emerging therapies such as remibrutinib, which is expected to generate over USD 1.5 billion in revenue across the 7MM by 2034.

Get a sneak peek at the Chronic Spontaneous Urticaria Market Dynamics @ Chronic Spontaneous Urticaria Market Dynamics Analysis 

Chronic Spontaneous Urticaria Companies

Sanofi/Regeneron Pharmaceuticals, Celldex Therapeutics, Novartis, Sanofi, Incyte, Jasper Therapeutics, Evommune, and others.

Chronic Spontaneous Urticaria Market Drivers

Demand for Chronic Spontaneous Urticaria therapies is primarily driven by the rising prevalence of the condition, with total diagnosed prevalent cases of chronic urticaria in the 7MM reaching approximately 4.5 million in 2024. Additionally, increasing adoption of self-administration options, the recent approval of targeted biologics like DUPIXENT, growing clinical trial activity featuring promising candidates including barzolvolimab (CDX-0159), remibrutinib (LOU064), rilzabrutinib, povorcitinib, and briquilimab, and technological advancements in drug delivery systems are contributing factors driving market growth during the forecast period from 2025 to 2034.

Which key players in the Chronic Spontaneous Urticaria Market are set to emerge as the trendsetter explore @ Chronic Spontaneous Urticaria Companies

Scope of the Chronic Spontaneous Urticaria Market Report

• Coverage: 7MM (US, EU4, UK, and Japan)

• Study Period: 2020–2034

• Forecast Period: 2025–2034

• Chronic Spontaneous Urticaria Companies: Sanofi/Regeneron Pharmaceuticals, Celldex Therapeutics, Novartis, Sanofi, Incyte, Jasper Therapeutics, Evommune, and others

• Epidemiology Segmentation: Total diagnosed prevalent cases of chronic urticaria, type-specific cases, gender-specific cases, age-specific cases, and severity-specific cases of Chronic Spontaneous Urticaria

Interested in knowing the Chronic Spontaneous Urticaria Market by 2034? Click to get a snapshot of the @ Chronic Spontaneous Urticaria Market Trends 

Table of Contents

1. Key Insights

2. Report Introduction

3. Chronic Spontaneous Urticaria Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Methodology

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. Chronic Spontaneous Urticaria – 7MM Market Analysis

13. Key Opinion Leaders’ Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us 

Kanishk

kkumar@delveinsight.com